Literature DB >> 7042003

Low serum thymic hormone levels in patients with chronic graft-versus-host disease.

K Atkinson, G S Incefy, R Storb, K M Sullivan, T Iwata, M Dardenne, H D Ochs, R A Good, E D Thomas.   

Abstract

We tested the hypothesis that chronic graft-versus-host disease (GVHD) is due to inadequate thymic function by examining pretransplant serum levels of facteur thymique serique (FTS). Four of five patients with no detectable FTS activity developed chronic GVHD, while one of four with some FTS activity did. Further patient numbers are needed to confirm or reject this hypothesis. We further postulated that chronic GVHD, whatever its cause, involves thymic epithelium as a target organ. When tested 11 mo or more posttransplant, patients with chronic GVHD had lower absolute FTS levels (p less than 0.02) and lower age-corrected levels (p = 0.05) than patients without chronic GHVD. Low values in chronic GVHD were associated with the disease itself and not its therapy. These findings show that thymic epithelial secretory function is impaired in chronic GVHD, and this may in part be responsible for the immunodeficiency characteristic of these patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7042003

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease.

Authors:  Jennifer L Lockridge; Ying Zhou; Yusof A Becker; Shidong Ma; Shannon C Kenney; Peiman Hematti; Christian M Capitini; William J Burlingham; Annette Gendron-Fitzpatrick; Jenny E Gumperz
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-24       Impact factor: 5.742

2.  Complete sequential regeneration of graft-vs.-host-induced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs.-host disease.

Authors:  T Ghayur; T A Seemayer; A Xenocostas; W S Lapp
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

3.  Circulating thymic hormone activity in young cancer patients.

Authors:  R Consolini; B Cei; P Cini; E Bottone; L Casarosa
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

Review 4.  Chronic graft-versus-host disease: Pathogenesis and clinical management.

Authors:  José A Pérez-Simón; Ignacio Sánchez-Abarca; María Díez-Campelo; Dolores Caballero; Jesús San Miguel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Pathology of the thymus after allogeneic bone marrow transplantation in man. A histologic immunohistochemical study of 36 patients.

Authors:  H K Müller-Hermelink; G E Sale; B Borisch; R Storb
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

Review 6.  Recent advances in the treatment of graft-versus-host disease.

Authors:  Tsuyoshi Iwasaki
Journal:  Clin Med Res       Date:  2004-11

7.  Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age.

Authors:  Emilie Castermans; Muriel Hannon; Jacques Dutrieux; Stéphanie Humblet-Baron; Laurence Seidel; Rémi Cheynier; Evelyne Willems; André Gothot; Jean-François Vanbellinghen; Vincent Geenen; Brenda M Sandmaier; Rainer Storb; Yves Beguin; Frédéric Baron
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

Review 8.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

9.  Growth hormone treatment stimulates thymulin production in aged dogs.

Authors:  B L Goff; J A Roth; L H Arp; G S Incefy
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

Review 10.  The pathophysiology of chronic graft-versus-host disease.

Authors:  Emin Kansu
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.